Archangels - Making The Future

News

Lab901 delivers next-generation system to Oxford Gene Technology

ScreenTape R6K is a next-generation platform for RNA QC that automatically delivers the ScreenTape Degradation Value (SDV), an objective quality metric for total RNA samples.

Lab901 today announced that it has shipped the first of its next-generation ScreenTape® systems for automated RNA QC to Oxford Gene Technology (OGT) in Oxford, UK. ScreenTape R6K is a next-generation platform for RNA QC that automatically delivers the ScreenTape Degradation Value (SDV), an objective quality metric for total RNA samples. Lab901's ScreenTape platform eliminates steps such as gel reagent preparation, chip priming and chip-vortexing, and avoids all problems associated with cross priming and sample carry-over since individual micro-gels are used for each sample analysis.

"As OGT's microarray R&D and service business grows, we are continually seeking opportunities to increase throughput whilst maintaining the highest standards of data quality" commented John Anson, R&D Director at OGT.  "Having evaluated Lab901's ScreenTape platform, we are keen to integrate it into our high throughput microarray facility." Commenting on the placement, Richard Rowling, Lab901's Sales and Marketing Director said: "Being the pioneer of microarray-based technologies, we are particularly delighted that OGT has decided to add ScreenTape R6K to their RNA QC workflow."

Unlike the leading chip-based systems, Lab901's ScreenTape device can be used more than once. A single sample can be run cost-effectively each time, reserving the rest of the available channels for future experiments. There is no longer any need to batch samples together or throw away unused portions of the consumable, which improves the RNA QC workflow and saves money.

For more information on Lab901's range of ScreenTape products for automated RNA QC, SDS-PAGE and multiplex PCR diagnostics please visit http://www.lab901.com/ or call Lab901 on +44 131 448 2904


 

Back to list

Latest News

Touch Bionics unveils the new i-LIMB Pulse

05 May 2010
Touch Bionics today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the wordl's first commercially available bionic hand. The i-LIMB Pulse is a significant advance for the i-LIMB product line, with a host of enhancements, including pulsing grip strength, software-enabled grip patterns and robust aluminium features for improved strength.

Touch Bionics wins prestigious Queen's Award for innovation

21 Apr 2010
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced it is a winner of the prestigious Queen's Awards for Enterprise with an award in the Innovation category for 2010. The Queen's Awards for Enterprise are the UK's most prestigious awards for business performance.

Bloxx Delivers Web Filtering Excellence at Wellingborough School

21 Apr 2010
School has immediate access to safe internet surfing with Bloxx Web Filtering. Bloxx today announced that Wellingborough School is providing safe Internet access for around 900 users and achieving superior anonymous proxy detection by using Bloxx's real time Web filtering, powered by its patented Tru-View Technology.

Bloxx helps Yorkshire Building Society keep staff safe online

15 Apr 2010
Bloxx the innovator in Web content filtering, announced on 15th April that Yorkshire Building Society is using Bloxx Web filtering to monitor and report on the Web browsing activity of over 2,000 staff, delivering superior protection from imappropriate or productivity impacting content and minimising network security risks.

New "Penicillin" for the 21st Century

01 Apr 2010
Today MGB Biopharma Limited, a late preclinical stage biopharmaceutical company, has commenced operations in Glasgow, UK to develop and commercialise a new class of antibacterial product: DNA Minor Groove Binders.